CD274 and non-small cell lung carcinoma: To the best of our knowledge, this is the first study to compare the efficacy and safety of atezolizumab plus chemotherapy and atezolizumab monotherapy in advanced NSCLC patients with high PD-L1 expression through indirect analysis.